Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals develops novel therapeutics based on RNA interference. Marketed products include ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. The company also develops treatments for various diseases, including transthyretin amyloidosis, complement-mediated diseases, and more. Alnylam has collaborations with Regeneron Pharmaceuticals and Roche to develop RNAi therapeutics. It also has license and collaboration agreements with Novartis AG, Vir Biotechnology, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

330.6 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (625.95) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0